When was IVENIX acquired by FRESENIUS?

IVENIX was acquired by FRESENIUS in 2022.

How is the data for the IVENIX acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the IVENIX deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.fresenius.com/10279

← DATABASE

Home Database Healthcare & PharmaIVENIX

03/2022

IVENIX acquired by FRESENIUS

UNITED STATES Life Sciences / Medical Devices / Diagnostic Equipment REV 1m USD - 100m USD

Context

Fresenius Kabi agreed to acquire 100% of Ivenix, delivering on its "Expand MedTech" growth vector under its Vision 2026 strategy. The combination of Ivenix's leading hardware and software infusion platform with Fresenius Kabi's existing intravenous fluids and infusion device portfolio creates a comprehensive premium MedTech offering for the US market. Significant scale and growth synergies are expected from the transaction. The Ivenix Infusion System is expected to be neutral to Fresenius Kabi's Group cash earnings per share in 2025 and accretive from 2026 onwards.

By taking control of Ivenix, Fresenius continues its expansion strategy. Previously, the group had completed 2 acquisitions, including Eugin Group in 2020.

IVENIX, which reported an EBITDA margin of in 2022, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Ivenix is a privately held US-based medical technology company specialising in next-generation infusion therapy systems. The company has developed what is considered the technologically most advanced infusion system available, comprising a large volume pump (LVP) with administration sets, infusion management software tools, applications, and analytics designed to improve care delivery and operational efficiency. The Ivenix Infusion System sets a new standard in infusion safety, simplicity, and interoperability, centred around the patient and clinician experience, and is specifically designed to reduce infusion-related errors and lower the total cost of ownership for healthcare providers. The system received FDA approval and was successfully commercially launched in the United States in late 2021.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2022

2021

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
05/2022	GOLDMAN SACHS	NORGINE	NETHERLANDS	Generics / Labs
05/2022	ASTORG	CORDENPHARMA	SWITZERLAND	CDMO
03/2022	FRESENIUS	MABXIENCE	SPAIN	CDMO
02/2022	MONTAGU PRIVATE EQUITY / PARTNERS GROUP	HTL BIOTECHNOLOGY	FRANCE	CDMO
01/2022	PERMIRA	BIO PRODUCTS LABORATORY (BPL)	UNITED KINGDOM	CDMO
01/2022	ANJAC BEAUTY & HEALTH	APOLLO HEALTHCARE CORP.	CANADA	CDMO
01/2022	ARDIAN	BIOFARMA GROUP	ITALY	CDMO
01/2022	PERMIRA	KEDRION	ITALY	CDMO
12/2021	WINNCARE	PHARMAOUEST INDUSTRIES	FRANCE	Medical Devices
12/2021	THE CARLYLE GROUP / GTCR	RESONETICS	UNITED STATES	Medical Devices

REFERENCES

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of IVENIX by FRESENIUS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: fresenius